Laddar...
Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
BACKGROUND: Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which also included patients with distant metastases and...
Sparad:
| I publikationen: | J Immunother Cancer |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BMJ Publishing Group
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7898852/ https://ncbi.nlm.nih.gov/pubmed/33608376 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001701 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|